Canada Approves Novavax's COVID-19 Vaccine As Booster In Adults

Health Canada has granted expanded approval to Novavax Inc's NVAX Nuvaxovid (COVID-19 Vaccine as a homologous booster in adults aged 18 and older.
The expanded authorization was based on data from a Phase 2 trial conducted in South Africa and the Prevent-19 Phase 3 trial conducted in the U.S. and Mexico.
Related: Novavax Posts Unexpected Q3 Loss, But Revenue Surpass Expectations.
As part of the trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six to 11 months after their primary series of two doses administered three weeks apart.
The third (booster) dose produced increased immune responses to levels comparable to or exceeding those associated with protection against COVID-19 in Phase 3 clinical trials.
In the trials following the booster, local and systemic reactions had a median duration of approximately two days. The incidence of Grade 3 or higher events remained relatively low.
Price Action: NVAX shares are down 4.95% at $19.76 on the last check Friday.
Photo by Jernej Furman via Flickr

Momentum11.96

GrowthNot Available

QualityNot Available

Value46.21

Short

Medium

Long